Milestone Pharmaceuticals operates as a biopharmaceutical enterprise dedicated to the development and commercialization of innovative cardiovascular medicines designed to transform the treatment of episodic cardiac conditions. Its primary focus centers on the clinical advancement and commercial rollout of its flagship investigational product, etripamil, which is a novel, rapid-onset calcium channel blocker engineered as a convenient nasal spray for self-administration by patients experiencing rapid heart rate episodes such as paroxysmal supraventricular tachycardia. By empowering patients to treat acute medical episodes outside of traditional emergency room settings, the company aims to improve patient quality of life, reduce urgent care visits, and expand therapeutic applications into adjacent cardiovascular indications like atrial fibrillation.